BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher?

Most of 2025 has been disappointing for BioAge Labs (NASDAQ: BIOA) shareholders, but things are looking up. During the week that ended Oct. 25, shares of the obesity drug developer soared by 46.6%.On Oct. 22, Samantha Semenkow, a sell-side analyst at Citigroup, upgraded her bank's rating on BioAge Labs from neutral to buy. Semenkow also raised her price target to $10 per share.Citi's new price target for BioAge Labs implies a gain of about 32% from the stock's closing price on Oct. 24. Unfortunately, those gains are a long way from guaranteed. Let's gauge this stock's ability to continue outperforming by looking at what drove it higher, and at the road ahead for its experimental weight management drugs.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool